

DECEMBER NEWSLETTER

Saskatchewan Respiratory Therapy Education Committee



Biologics for Treatment of Asthma

AN OVERVIEW OF BIOLOGIC TREATMENT OPTIONS FOR ASTHMA PATIENTS

- Asthma is a heterogeneous disease affecting an estimated 339 million people worldwide. Severe asthma requires treatment with high-dose ICS-LABA and/or systemic corticosteroids, to achieve asthma control.
- GINA reports an estimated prevalence of severe asthma in 3.7% of asthma patients.
- Type 2 asthma is the most common phenotype, affecting approximately 50–70 % of patients with asthma
- Type-2 targeted biologic therapy should be considered for patients with exacerbations or poor symptom control on high dose ICS-LABA, who have evidence of Type 2 inflammation.
- Biologic therapy reduces exacerbations and hospitalizations, improves lung function, asthma control and quality of life, and reduces the use of systemic corticosteroids, with a favourable safety profile. These effects were more prominent in patients with evidence of T2 inflammation, with some evidence for the efficacy of tezepelumab also in patients with Type 2-low asthma.
- Special consideration with Reslizumab as it's given intravenously, while all other biologic treatments are given subcutaneously.
- Tezepelumab (anti-TSLP), Dupilumab (anti-IL4R-alpha), Mepolizumab (anti-IL5/anti-IL5R), Benralizumab (anti-IL5/anti-IL5R), Omalizumab (anti-IgE), and Reslizumab (anti-IL5/anti-IL5R) are the current biologic treatments available for asthma patients.
- Tezepelumab is the first biologic to receive an indication for severe asthma irrespective of the presence of type 2 inflammation.

**RT: "HOW LONG HAVE YOU
BEEN HAVING BREATHING
TROUBLES?"**

PATIENT: "IT'S A LUNG STORY"

**SOCIAL MEDIA HIGHLIGHT:
@GINASTHMA**

**THE NEXT QUARTERLY
WEBINAR WILL BE DECEMBER
11TH AT 6PM CST.
DR. UBHI WILL BE
DISCUSSING NEW
MANAGEMENT FOR COPD AND
ASTHMA.
THANK YOU TO ASTRazeneca
FOR THE SPONSORSHIP.
YOU CAN ACCESS THE EVENT
VIA THIS [LINK](#).**

Educational Resources

BIOLOGICS FOR TREATMENT OF ASTHMA

ARTICLE RESOURCES

- [Biologic agents licensed for severe asthma: a systematic review and meta-analysis of randomised controlled trials](#)
- [Recent Advances in biological targeted therapies for bronchial asthma \(2024\)](#)
- [Biologic Medications for Severe Asthma: Implications for Understanding Pathogenic Heterogeneity and Endotypes](#)

If you're having difficulty accessing the articles SHA Library Services is a great resource available to all SHA employees. Feel free to contact them to setup a library card number to obtain off site access.

WEBINARS

- [The Basics of Biologics presented by the Asthma & Allergy Network](#)
- [Applying the Latest Guidelines to Control Moderate-to-Severe Asthma Symptoms](#)
- [Biologic Therapy for Patients with Severe Asthma](#)

VIDEO RESOURCES


- [Rubin allergy on breakthrough treatment of asthma](#)
- [Biologics Available for Asthma](#)
- [Biologics in Asthma/COPD](#)

PODCASTS

- [PulmPEEPS 98. Guidelines Series: GINA Guidelines - Biologics for Treatment of Asthma](#)
- [Navigating the Expanding Spectrum of Biologics](#)
- [ATS Breathe Easy - Biologics: A Breakthrough Treatment for Asthma](#)

SUMMARIES & GUIDELINES

- [GINA Guidelines 2024 Difficult-To-Treat & Severe Asthma](#)



Thank you to everyone who sent in nominations for the BOMImed Respiratory Therapy Excellence Award.

We will be announcing a winner soon.

As we continue to grow this committee we are finding a need for more members.

If you're interested in joining the SaskRTEC please send us an email at saskrtec@gmail.com